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Abstract
Background: Antivirals play a critical role in the prevention and the management of influenza. One class of
antivirals, neuraminidase inhibitors (NAIs), is effective against all human influenza viruses. Currently there are two
NAI drugs which are licensed worldwide: oseltamivir (Tamiflu
®) and zanamivir (Relenza
®); and two drugs which
have received recent approval in Japan: peramivir and laninamivir. Until recently, the prevalence of antiviral
resistance has been relatively low. However, almost all seasonal H1N1 strains that circulated in 2008-09 were
resistant to oseltamivir whereas about 1% of tested 2009 pandemic H1N1 viruses were found to be resistant to
oseltamivir. To date, no studies have demonstrated widespread resistance to zanamivir. It seems likely that the
literature on antiviral resistance associated with oseltamivir as well as zanamivir is now sufficiently comprehensive
to warrant a systematic review.
The primary objectives were to systematically review the literature to determine the incidence of resistance to
oseltamivir, zanamivir, and peramivir in different population groups as well as assess the clinical consequences of
antiviral resistance.
Methods: We searched MEDLINE and EMBASE without language restrictions in September 2010 to identify studies
reporting incidence of resistance to oseltamivir, zanamivir, and peramivir. We used forest plots and meta-analysis of
incidence of antiviral resistance associated with the three NAIs. Subgroup analyses were done across a number of
population groups. Meta-analysis was also performed to evaluate associations between antiviral resistance and
clinical complications and symptoms.
Results: We identified 19 studies reporting incidence of antiviral resistance. Meta-analysis of 15 studies yielded a
pooled incidence rate for oseltamivir resistance of 2.6% (95%CI 0.7% to 5.5%). The incidence rate for all zanamivir
resistance studies was 0%. Only one study measured incidence of antiviral resistance among subjects given
peramivir and was reported to be 0%. Subgroup analyses detected higher incidence rates among influenza A
patients, especially for H1N1 subtype influenza. Considerable heterogeneity between studies precluded definite
inferences about subgroup results for immunocompromised patients, in-patients, and children. A meta-analysis of 4
studies reporting association between oseltamivir-resistance and pneumonia yielded a statistically significant risk
ratio of 4.2 (95% CI 1.3 to 13.1, p = 0.02). Oseltamivir-resistance was not statistically significantly associated with
other clinical complications and symptoms.
Conclusion: Our results demonstrate that that a substantial number of patients may become oseltamivir-resistant
as a result of oseltamivir use, and that oseltamivir resistance may be significantly associated with pneumonia. In
contrast, zanamivir resistance has been rarely reported to date.
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Description of the Condition
Influenza (the flu) is an acute infection of the upper
respiratory tract which is transmitted via respiratory
droplets and direct contact. Immunocompromised peo-
ple and those with underlying cardio-pulmonary condi-
tions are considered at increased risk from serious
influenza-related complications. Annually, influenza
infection results in more than 500, 000 deaths world-
w i d e[ 1 ] .T h ei n f l u e n z av i r u si sa nR N Av i r u st h a t
belongs to the Orthomyxoviridae family [2]. There are
two main types of influenza virus: type A and type B
[2]. These two types are responsible for seasonal flu epi-
demics each year. The influenza virus is continually
evolving and under immune pressure; it may either
evolve through small gradual changes in the virus (anti-
genic drift) or through abrupt major changes in the
virus (antigenic shift) most frequently by genetic reas-
sortments [3]. Such changes can result in the emergence
of new influenza viruses that can cause pandemics (e.g.,
the 1918 Spanish flu pandemic and the 2009 H1N1 pan-
demic)[4].
Description of the interventions
Vaccines play a critical role in the prevention of influ-
enza [5]. Nevertheless, the efficacy of this intervention
could be significantly reduced owing to a mismatch
between the seasonal influenza vaccine and the circulat-
ing influenza virus and the inability of the host to
mount a proper immune response [6]. Therefore, anti-
virals also play an important role in the prevention and
management of influenza. There are two classes of anti-
viral agents for influenza: adamantanes and neuramini-
dase inhibitors. Adamantanes (amantadine and
rimantadine), however, are not recommended alone for
the treatment of influenza due to their lack of activity
against influenza B and the high level of influenza A
resistance [6,7]. Neuraminidase inhibitors (NAIs) are
effective against all human, avian and animal influenza
viruses [6-8]. NAIs inhibit the release of virions by com-
petitively inhibiting viral NA, which is a key glycopro-
tein at the surface of the virus. Currently there are two
NAIs drugs which have been approved worldwide: Osel-
tamivir (Tamiflu
®) and Zanamivir (Relenza
®). Both
drugs are approved for treatment of acute uncompli-
cated illness due to influenza A and B, and are also
approved for preventive use [9]. Oseltamivir is provided
orally to persons older than one year who have been
symptomatic for no more than 2 days [9]. Zanamivir is
provided as a dry powder which is given by inhalation
in persons aged 7 years and older who have been symp-
tomatic for no more than 2 days [9].
Peramivir is an intravenous neuraminidase inhibitor
under development for the treatment of influenza. In
October 2009, the FDA issued an Emergency Use
Authorization (EUA) for the use of peramivir based on
safety data from Phase 1, Phase 2 trials, and limited
Phase 3 trial data. The EUA for peramivir expired in
June 2010. However, peramivir has been approved in
Japan and Korea. More recently, laninamivir, a long-last-
ing inhaled neuraminidase inhibitor has also been
licensed in Japan [10,11].
Antiviral resistance
Influenza A and B strains had remained susceptible to
oseltamivir with rare exceptions since their availability
in 1999. Recent reviews and expert opinions have identi-
fied studies reporting prevalence and incidence rates of
antiviral resistance among patients treated with oselta-
mivir [6,7]. Until recently, the prevalence of antiviral
resistance had been relatively low [12,13]. However, in
the influenza season 2008-2009, the Centers for Disease
Control and Prevention (CDC) reported a worldwide
significant increase in the prevalence of oseltamivir
resistance to influenza A/H1N1 viruses (A/Brisbane/59/
2007-like strains) due to the H275Y NA mutation [9].
Furthermore, about 1% of tested 2009 pandemic H1N1
viruses (A/California/07/2009 (H1N1) - like strain) were
found to be resistant to oseltamivir due to the same
mutation. Finally, a Japanese study published in 2004
reported incidence of antiviral resistance in hospitalized
children as high as 18%[14].
To date influenza A and B, including all types of A/
H1N1 virus, remain susceptible to zanamivir. Further, a
recent review only found one documented case of zana-
mivir resistance [6,15]. Oseltamivir is easier to adminis-
ter and has therefore been used vastly more than
zanamivir. For this reason, most literature on antiviral
resistance associated with NAIs has only investigated
antiviral resistance associated with oseltamivir. However,
owing to the higher resistance rates associated with osel-
tamivir, especially for A/H1N1 strains between 2007-09,
zanamivir has been increasingly utilized for the treat-
ment and prevention of influenza [9]. Therefore, there is
a need to investigate the development of influenza resis-
tance to zanamivir in this time period. Studies investi-
gating resistance to peramivir may also have emerged.
We therefore conducted a systematic review using
comprehensive literature search strategies to identify
and systematically assess all relevant studies on antiviral
resistance associated with oseltamivir, zanamivir, and
peramivir.
Objectives
Primary objective
Our primary objective was to systematically review the
literature to determine the incidence of resistance to
oseltamivir, zanamivir, and peramivir in adult
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treatment of influenza. We did not consider lananimivir
since it was not licensed at the time we commenced this
review.
Secondary objectives
Our secondary objectives were to
1) Systematically review data from the literature to
determine the incidence of resistance to oseltamivir,
zanamivir, and peramivir in different patient popula-
tions (e.g., hospitalized, immunocompromised, chil-
dren, and others).
2) Assess the clinical consequences of antiviral resis-
tance (clinical complications and symptoms asso-
ciated with antiviral resistance, and severity of
complications and symptoms among resistant
patients).
Methods
Criteria for considering studies for this review
Types of studies
We included randomized clinical trials (RCTs), cohort
and case-control studies, and case reports.
Types of patients
We included adult immunocompetent outpatients for
our primary objective. For our secondary objective we
included patients if they were children, immunocompro-
mised, or hospitalized.
Types of interventions
We included studies that reported incidence of antiviral
resistance associated with one or more of the three
NAIs oseltamivir, zanamivir, and peramivir. We
included all studies regardless of the dose and length of
follow-up. We did not include studies where an NAI
was administered in combination with another antiviral
(e.g., rimantadine)
Types of outcomes
Our primary and first secondary outcome of interest
was incidence of antiviral resistance and our secondary
outcomes of interest were the clinical consequences
associated with antiviral resistance.
Viral resistance is detected either by the presence of
resistance-associated mutations such as the H274Y (N2
numbering) or H275Y (N1 numbering) substitution or
by measuring the median 50% inhibitory concentration
(IC50). Commonly used laboratory criteria for determin-
ing known antiviral resistance is a substantially elevated
IC50 value by enzyme inhibition assay (a value greater
than 10-fold that of the corresponding parent virus or
greater than three standard deviation (SD) compared to
the mean value [13,16]. For example, for the H1N1
virus with the most frequent H275Y NA mutation, the
observed IC50 values are usually 200- 400 fold higher
than the mean IC50 value [17-21]. However, the defini-
tion of antiviral resistance is not standardized and could
differ for each of the three NAIs, and may also vary
across included studies (due to pre-specification of a
threshold or different assays). For that reason, we used
the definition of resistance as outlined in the studies to
determine the incidence of antiviral resistance.
Measured influenza outcomes included duration of
antiviral shedding, the peak viral titers, and the days to
resolution of influenza symptoms. For studies reporting
on clinical consequences of antiviral resistance, we
reported all influenza related complications and
symptoms.
Electronic searches and data retrieval
We searched MEDLINE and EMBASE without language
restrictions in September 2010. We limited the search
strategy to human studies. We also manually searched
reference lists from recent review articles.
Study selection and Data Extraction
Two reviewers (KT and TA) independently reviewed the
abstracts for potential eligibility and subsequently full
text publications for eligibility. Disagreements were
resolved by discussion.
We extracted a number of variables on study design
and methodological characteristics, patient and interven-
tion characteristics, and outcomes from all eligible stu-
dies (see appendix). Data extraction was done
independently by two reviewers (KT and TA) and dis-
agreements were resolved by discussion.
Methodological Quality Assessment
For the RCTs, we assessed the adequacy of the methods
used for randomization, allocation concealment, blind-
ing, and follow-up [22,23]. We scored the quality for
each RCT by assigning one point for each adequate
item. With this scale, RCTs can score a minimum of 0
points and a maximum score 4 points. We considered
RCTs that scored at least 3 points as high quality. We
used the Newcastle-Ottawa Scale (NOS) to assess the
adequacy of the employed methodology in the retrieved
observational studies [24]. For observational studies
reporting incidence of antiviral resistance, there were no
control groups. We therefore used a modified version of
the NOS scale for cohort studies, taking out the three
items that dealt with adequacy of controls or compari-
son between exposed and non-exposed individuals.
With this scale, incidence studies can score a minimum
of 0 points and a maximum of 6 points. We considered
studies that scored at least 5 points as high quality. For
observational studies reporting on consequences of anti-
viral resistance, we used the complete NOS scale. With
this scale, incidence studies can score a minimum of 0
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dies that scored at least 7 points as high quality.
Statistical analysis and reporting of results
We calculated the antiviral resistance incidence rate and
the associated 95% confidence interval (CI) for all stu-
dies and study subgroups. Antiviral resistance incidence
rate was calculated as the proportion of patients who
developed resistance. We calculated the 95% CI based
on the assumption that the incidence rate followed a
binomial distribution. For incidence rates equal to 0%,
we used the “rule of threes” to calculate the upper 95%
CI upper bound [25]. This rule says that the 95% CI
upper bound is equal to 3/n, where n is the sample size.
Primary objective - estimating incidence
We calculated the antiviral resistance incidence rate and
the associated 95% CI for all studies (and subgroups)
involving immunocompetent adult out-patients. We
produced forest plots and pooled incidence rates across
studies using the arcsine method [26].
Secondary objective - incidence across subgroups
We first performed subgroup analysis on type of NAIs
(oseltamivir, zanamivir, or peramivir) and pooled inci-
dence rates within each subgroup using the arcsine
method [26]. For each type of NAIs, we then performed
subgroup analyses for study design, type of influenza,
immunocompetent/immunocompromised patients, out
patients/hospitalized patients, adults/children, and pro-
phylaxis/treatment and produced corresponding forest
plots. We did not produce pooled estimates in these
subgroups.
Secondary objective - consequences of antiviral resistance
We qualitatively compared the mean, median, mini-
mum, and maximum duration of antiviral shedding, the
peak viral titers, and the days to resolution of influenza
symptoms reported in the identified incidence studies.
We reported odds ratios and risk ratios for associa-
tions between antiviral resistance and clinical complica-
tions or symptoms. Whenever possible, these ratios
were combined in a random-effects meta-analysis and
presented in a forest plot. Adjusted ratios obtained from
multivariate models were preferred to crude ratios. If
possible, risk ratios were converted to odds ratios.
For resistant patients reported in case reports, we cre-
ated a qualitative overview (a table) of clinical complica-
tions (e.g., pneumonia) and symptoms which authors
believed could be associated with resistance.
Results
Our search resulted in 1289 hits after removal of dupli-
cate citations. Figure 1 presents the PRISMA diagram
for our eligibility scan. A total of 43 study reports were
eligible. Among these, ten were randomized clinical
trials (RCTs) that reported incidence of antiviral resis-
tance,[27-36] (effectively fourteen since two publications
reported results from four and three RCTs respectively)
and nine were cohort studies that reported incidence of
antiviral resistance [14,37-44]. Four were case-control
studies that reported associations between antiviral
resistance and clinical symptoms or complications
[45-48]. Lastly, 21 were case reports comprising reports
on a total of 27 patients [15,49-68]. None of the ten
RCTs or the nine cohort studies made head to head
comparisons between any two of the three NAIs (i.e., all
19 studies only included one NAI arm). Thirteen studies
measured incidence of antiviral resistance among sub-
jects given oseltamivir,[14,31,33,35,37-44], five studies
measured incidence of antiviral resistance among sub-
jects given zanamivir,[27,29,30,32,34] and only one study
measured incidence of antiviral resistance among sub-
jects given peramivir [28]. Four oseltamivir studies and
all zanamivir and peramivir studies were RCTs. The
Figure 1 PRISMA diagram of literature search and eligibility
scan. Study reports were excluded if 1) they were expert opinions,
commentaries, letters or reviews; 2) if it was clear that they did not
include either oseltamivir, zanamivir, or peramivir treated patients; or
3) if it was clear that none of the considered outcomes could be
extracted.
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between oseltamivir resistance and clinical complica-
tions and symptoms. Among the 21 case reports, 17
reported on resistance to oseltamivir only, and 2 on
resistance to zanamivir only, and 2 on resistance to
both. In 12 of the 21 case reports (13 out of 27 patients)
where oseltamivir was the initial treatment, patients
were eventually switched to zanamivir.
Most studies that reported incidence of antiviral resis-
tance included a mix of our pre-specified subgroups.
The methodological quality, the patient characteristics,
and the intervention characteristics of the incidence stu-
dies are presented in table 1. All RCTs were of high
quality. Only one incidence study was low quality
according to the modified NOS. The four case-control
studies that reported associations between antiviral
resistance and clinical symptoms and complications all
scored between 7/9 and 9/9 on the NOS.
Primary objective - estimating incidence
Most studies included a mix of the considered sub-
groups but did report results separately for each sub-
group. It was therefore only possible to extract data
from five studies for our primary objective: incidence of
resistance among adult immunocompetent out-patients
[27-31]. Among these five studies, one reported inci-
dence of antiviral resistance associated with oseltamivir,
three reported incidences of antiviral resistance asso-
ciated with zanamivir, and one reported incidences of
antiviral resistance associated with peramivir. In all five
studies, patient recruitment ended in or before year
2000. Incidence of resistance was 0% in all five studies
[27-31]. For this reason we did not produce a forest
plot.
Secondary objective - incidence across subgroups
Figure 2 shows the incidence of antiviral resistance sub-
grouped by NAI (oseltamivir, zanamivir, and peramivir).
The pooled incidence rate for oseltamivir was 2.6% (95%
CI 0.7% to 5.5%). However, the estimated heterogeneity
was I
2 = 90%. The incidence rate for all zanamivir stu-
dies was 0%. All zanamivir studies were RCTs. Further,
all zanamivir studies ended in or before year 2000. Only
one study measured incidence of antiviral resistance
among subjects given peramivir and was reported to be
0%.
Because antiviral resistance was only observed in osel-
tamivir studies, we did not produce subgroup forest
plots including zanamivir or peramivir studies. Figure 3
presents the forest plot of incidence of antiviral resis-
tance to oseltamivir subgrouped by influenza type. The
remaining subgroup forest plots of incidence of antiviral
resistance are presented in additional files 1, 2, 3, 4 and
5 (figures A.1 to A.5).
Antiviral resistance was observed among A/H1N1
patients in 5 of 6 studies with incidence rates varying
from 3.6% and 27.3%. Among influenza A/H3N2
patients, incidence rates across three studies were 0%,
3.3%, 18%. Incidence rates among influenza B patients
were 0% in two studies and 2% in one study (see figure
3). Antiviral resistance rates in prophylaxis studies were
either 0% or low (4%), whereas more than half of the
treatment studies reported resistance rates above 5%
(see additional file 1, figure A.1).
Our subgroup analyses on RCTs versus observational
studies, immunocompetent versus immunocompromised,
out-patients versus in-patients, and adults versus children
did not yield any apparent differences between sub-
groups. The lack of apparent differences was, in part, due
to the large degree of heterogeneity within subgroups. All
remaining subgroup analyses are presented in the appen-
dices (see additional files 2, 3, 4 and 5 (figures A.2-A.5)).
Secondary objective - consequences of antiviral resistance
Figure 4 shows the forest plot of risk ratios for associa-
tion between oseltamivir resistance and clinical compli-
cations that were reported in more than one study. The
meta-analysis of the association between oseltamivir-
resistance and pneumonia yielded a statistically signifi-
cant risk ratio (RR 4.16, 95% CI 1.28 to 13.1, p = 0.02).
The meta-analyses of the association with otitis yielded
a pooled risk ratio of 0.97 (95% CI 0.41 to 2.43). The
meta-analysis of the association with hospitalization
yielded a pooled risk ratio of 0.60 (95% CI 0.24 to 1.48).
The study by Hauge additionally reported adjusted risk
ratios for the associations with sinusitis (RR 1.7, 95% CI
0.4 to 7.5) and with bronchitis (RR 0.8, 95% CI 0.4 to
1.8)[47]. Two deaths were reported in the study by
Dharan [48]. However, these two patients died before
they were admitted to the hospital. No deaths were
reported in the other three identified association studies.
The meta-analyses of associations between oseltamivir
resistance and the clinical symptoms (cough, fever, sore
throat, myalgia, acute/sudden onset, runny nose and
headache), did not reveal any differences between oselta-
mivir-resistant and oseltamivir-susceptible patients. All
pooled risk ratio estimates were equal or very close to
1.00 and all 95% CIs included 1.00. The forest plots for
these meta-analyses are presented in additional file 6
and 7 (figure A.6). One study (Dharan) additionally
reported odds ratios on chills and breathing difficulty
[48]. Risk ratio estimates for these two symptoms were
close to 1.00 and had wide confidence intervals.
Table 2 provides a summary of the duration of illness
reported across association and incidence studies. Over-
all, the oseltamivir-resistant and oseltamivir-susceptible
patients seem to require the same number of days to
reach resolution of symptoms.
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complications associated with antiviral resistance. Table
3 summarized these complications in relation to the type
of treatment, patient group and influenza. The complica-
tions associated with antiviral resistance were typically of
a respiratory nature. Prolonged fever was also common.
In 9 case reports, oseltamivir resistant patients were
switched to zanamivir once viral resistance had been
detected. In some cases, patients seemed to recover as a
result of the switch, in others cases they did not.
Discussion
The primary focus of this review was to describe the
incidence of resistance to oseltamivir, zanamivir, and
peramivir in adult immunocompetent outpatients for
the prevention and treatment of influenza. However, we
Table 1 Baseline characteristics of studies reporting on incidence of resistance
Study Intervention Patients
Study first
author
Recruitment
Period
Design* Quality
score**
Purpose Dose Duration Immunostatus In/
Out
Age
group
Zanamivir studies
Boivin
31 1997-1998 RCT High Treatment 10 mg td 5 days Competent Out Unclear
Hedrick
36 1998-1999 RCT High Treatment 10 mg td 5 days Competent Out Children
Ambrozaitis
29 1997-2000 RCT High Prophylactic 10 mg td 14 days Competent In Adults
Gravenstein
32 1997-2000 RCT High Prophylactic 10 mg td 14 days Competent In Adults
Hayden(1)
34 1999-2000 RCT High Prophylactic 10 mg td 10 days Competent Out Adults
Peramivir study
Barosso(a)
30 1999-2000 RCT High Treatment 100, 200, or 400 mg qd, or 200 md
q12 h
5 days Competent Out Adults
Barosso(b)
30 1999-2000 RCT High Treatment 800 mg qd(day1) then400 mg q24
or 400 mg q24
5 days Competent Out Adults
Barosso(c)
30 1999-2000 RCT High Treatment 50, 200, or 400 mg qd 5 days Competent Out Adults
Barosso(d)
30 1999-2000 RCT High Treatment 200, 400 or 800 mg 5 days Competent Out Adults
Oseltamivir studies
Whitley
38 1998-1999 RCT High Treatment 2 mg/kg twice daily (max 100 mg/
day)
5 days Competent Out Children
Hayden(2)
35 2000-2001 RCT High Prophylactic 75 mg once daily 10 days Competent Out Mix
Hayden(3-a)
33 2000 RCT High Treatment 75 mg/150 mg once/twice daily 5 days Competent Out Adult
Hayden (3-b)
33 2000 RCT High Treatment 75 mg once daily 5 days Competent Out Adult
Hayden (3-c)
33 2000 RCT High Prophylactic 75 mg once daily 7 days Competent Out Adult
Ison
37 Before 2009 RCT High Prophylactic 75 mg orally or suspension once
daily for age = > 13, weight-based
or suspension for age < 13
12 days Compromised In Unclear
Kiso
15 2002-2003 OBS 6/6 Treatment 4 mg/kg 2-5 days Competent Mix Children
Kawai
42 2003-2004 OBS 6/6 Treatment 75 mg twice daily for adults and
children > 35 kg, weight-based
twice daily for children < 35 kg
5 days Unclear Out Mix
Hatekayama
41 2004-2005 OBS 5/6 Treatment Unclear Unclear Mix Unclear Children
Stephenson
43 2005-2007 OBS 6/6 Treatment Twice daily weight-based dosing
regimen
5 days Competent Unclear Mix
Cost
39 2009 OBS 4/6 Prophylactic Unclear Unclear Compromised In Children
Harvala
40 2009 OBS 6/6 Treatment Unclear Unclear Mix Unclear Unclear
Tramontana
44 2009 OBS 6/6 Treatment Varied across patients Up to 43
days
Compromised In Adults
Wang
45 2009 OBS 6/6 Treatment Unclear Unclear Mix In mix
Winzer
46 2009 OBS 5/6 Treatment Unclear Unclear Unclear Unclear mix
*Study design is either a randomized clinical trial (RCT) or an observational study (OBS)
**Quality scores for RCTs range from 1 to 4. Study scores for OBSs range from 1 to 6. Low scores indicate low quality, high scores indicate high quality.
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sions about this issue. The secondary focus of our
review was to describe the incidence and consequences
of antiviral resistance across various population groups.
Overall the incidence of oseltamivir-resistance across
studies was 2%. We found higher oseltamivir-resistance
incidence rates among influenza A patients - particularly
those of the H1N1 subtype. Zanamivir was associated
with 0% incidence of resistance. Only one study mea-
sured incidence of antiviral resistance among subjects
given peramivir and it was reported to be 0%. However,
zanamivir and peramivir clinical trials stopped enrolling
in year 2000 at the latest, and therefore have little gen-
eralizability. We did not compare the incidence rates
between drugs because there are no head-to-head stu-
dies that have compared these drugs. Our analyses of
consequences associated with development of antiviral
resistance demonstrated that oseltamivir-resistant
patients are approximately 4 times more likely to suffer
from pneumonia than oseltamivir-susceptible patients.
We did not find any associations between oseltamivir-
resistance and other clinical complications or symptoms.
We did not identify any studies reporting on association
between zanamivir or peramivir resistance and clinical
complications or symptoms. Our review of case reports
shows that antiviral resistance can be associated with a
number of serious complications. Such complications
are typically of a respiratory nature and may in some
cases be so severe that the patient will die, but whether
it depends on viral resistance or on the host’si m m u n e
response needs to be determined.
Our review comes with a number of strengths and
limitations. We collectively reviewed randomized clinical
trials, cohort studies, case series, and case reports. Ran-
domized clinical trials are typically conducted under
controlled settings that may not be entirely representa-
tive of general clinical practice. In the context of our
review, such controlled settings may substantially reduce
the risk of developing antiviral resistance. By including
Figure 2 Forest plots of antiviral resistance incidence among
oseltamivir studies subgrouped by neuraminidase inhibitor.
The numerator is the number of patients who developed resistance,
and the denominator is the number of patients that received an
NAI.
Figure 3 Forest plots of antiviral resistance incidence among
oseltamivir studies subgrouped by type of influenza. The
numerator is the number of patients who developed resistance, and
the denominator is the number of patients that received an NAI.
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estimates that are generalizable to conventional clinical
practice settings. Furthermore, our additional inclusion
of case reports allowed us to evaluate the severity of the
clinical complications that can arise from antiviral
resistance.
D e s p i t ei n c l u d i n gaw i d er a n g eo fc o n s i d e r e ds t u d y
designs, our review finds its limitations in the paucity of
evidence. We did not find any recent studies that inves-
tigated incidence of antiviral resistance associated with
zanamivir or peramivir, in fact, all studies on zanamivir
ended patients’ recruitment in 2000 at the latest. Thus,
we were unable to assess whether zanamivir and pera-
mivir still yields a (close to) 0% incidence of antiviral
resistance. In addition to the time factor, it is reported
that there is a cross-resistance association between osel-
tamivir and peramivir [49,69]. For patients infected with
A/H1N1 virus harboring the H275Y mutation, studies
conducted before the 2007-2009 seasons are therefore
likely to underestimate resistance to peramivir dramati-
cally. Furthermore, recent peramivir clinical trials have
evaluated a parenteral injection form instead of prior
oral tablets [28,70].
Most oseltamivir studies included a mix of population
subgroups and had little or no reporting on subgroup
results. As a result, much within-subgroup heterogeneity
ensued, and thus, many of our subgroup analyses did
not yield any ‘apparent’ differences. The presence of a
mixture of resistant and susceptible viruses especially in
immunocompromised hosts may also potentially
Figure 4 Forest plots of risk ratios for associations between antiviral resistance and clinical complications. The risk ratios from the
studies by Hauge and Ciancio are adjusted risk ratios obtained from multivariable models. The risk ratios from the Buchholz study are crude risk
ratios based on zero-event continuity correction of 0.5. The Dharan risk ratio was transformed from an adjusted odds ratio based on a
multivariable model.
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did not find any studies on incidence of antiviral resis-
tance among H5N1 patients, and only two case reports
on H5N1 patients [51,52]. As for case reports, it is likely
that our search may have missed a substantial number
of case reports due to such publications being poorly
indexed in the utilized search engines. We excluded
some case reports of oseltamivir resistance in H5N1
infected humans because no clinical data was reported
[71] or because resistance was detected pre-therapy [72].
The rates at which pneumonia occurred in oseltami-
vir-susceptible patients were between 1% and 3%[45-48].
Meanwhile, our meta-analysis suggests that oseltamivir-
resistant patients are 4-times more likely to suffer from
pneumonia. Assuming that 2% of oseltamivir-susceptible
patients suffer from pneumonia, 1 out of every 50 osel-
tamivir-susceptible patients would suffer from pneumo-
nia in comparison to 1 out of every 12 oseltamivir-
resistant patients. It is noteworthy that in the identified
case reports, many cases of resistance arose in immuno-
compromised patients adding a confounder in the inter-
pretation of this association.
Our review provides valuable insight on the incidence
of antiviral resistance associated with oseltamivir use.
However, we were not able to draw inferences about
incidence of antiviral resistance associated with zanami-
vir or peramivir use due to the absence of recent studies
on the topic. The reviewed case reports mainly involved
immunocompromised subjects who were hospitalized
(in-patients) and received oseltamivir as treatment
rather than prophylaxis. This could suggest a tendency
that notable complications associated with antiviral
resistance more frequently arise among such patients.
To confirm this, however, future cohort studies that
investigate the associations between antiviral resistance
and complications should incorporate patient and treat-
ment characteristics in the multivariate models.
Conclusion
Our results demonstrate that that a substantial number
of patients may become oseltamivir-resistant as a result
of oseltamivir use, and that oseltamivir resistance may
be significantly associated with pneumonia. In contrast,
zanamivir resistance has been rarely reported to date.
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Table 2 Summary of symptoms and days to resolution of symptoms reported across association studies and incidence
studies
Study Resistant patients Sensitive patients
n Reported symptoms and durations n Reported symptoms and durations
Association studies
Buchholz (2009)
48 11 Duration of sick leave:
Median: 7 days
IQR: 6 to 14
26 Duration of sick leave:
Median: 7 days
IQR: 7 to 10
Buchholz (2009)
48 38 Days confined to bed:
Median: 3.5 days
IQR: 2 to 7
93 Days confined to bed:
Median: 3 days
IQR: 2 to 5
Dharan (2009)
50 49 Activities limited: 1-7 days
Median: 4 days
97 Activities limited: 1-30 days
Median: 4 days
Dharan (2009)
50 38 Missed work or school: 1-10 days
Median: 4 days
97 Missed work or school: 1-30 days
Median: 4 days
Incidence studies
Kiso (2004)
15 9 Duration of fever: 2-7 days
Median = 3 days
41 Duration of fever: 1-6 days
Median = 3 days
Hatakeyama (2007)
41 1 Duration of fever: 2 days 76 Mean duration of fever: 2.4 days
Stephenson (2009)
43 4 Duration of fever: 5-6 days
Full recovery after: 9-10 days
60 Authors commented no difference observed
between resistant and sensitive patients
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Page 9 of 13Table 3 Summary of patient and treatment characteristics, and complications believed to be associated with antiviral
resistance in the reviewed case reports
Study Period Flu
type
Mutation Proph/
Treat
Competent/
Compromised
In/Out
Patient
Age Days to
resistance
detection
Complications associated with resistance
Oseltamivir resistance
Baz
52 2005-
2006
H3N2 E596G
E119V
I222V
I223V
Treat Compromised In 4 m 14 Respiratory complications, prolonged viral
shedding (about 90 days)
Baz
52 2009 H1N1 H275Y Postexp
Proph
Competent Out 59y 8 None. Recovered after 2 weeks
Campanini
55 2009 H3N2 H274Y Treat Compromised In 2y 18 42 days to resolution of flu symptoms
Cane
56 2010 H1N1 H275Y Treat Compromised In 3y NA 1 month to resolution of flu symptoms
CDC-Weekly(1)
57 2009 H1N1 H275Y
I223V
Proph Competent Out Teens 27 None ("uneventful recovery”)
CDC-Weekly(1)
57 2009 H1N1 H275Y
I223V
Proph Competent Out Teens 14 None ("uneventful recovery”)
CDC-Weekly(2)
48 2009 H1N1 H275Y Treat Compromised In Teens 30 2 months to recovery
CDC-Weekly(2)
48 2009 H1N1 H275Y Treat Compromised In 40y 30 2 months to revovery, prolonged neutron-
penia and protracted bone marrow
recovery, neutropenic fever, coagulase-
negative Staphylococcus bacteremia, and
Pneumocystis
Couturier(1)
59 2009 H1N1 H275Y Treat Compromised In 69y 9 Renal function declined. Died after 17 days.
Couturier(2)
59 2009 H1N1 H275Y Treat Compromised In 66y 21 Recovered after 1 month. Caught fever
again after 3 months and died.
Couturier(3)
59 2009 H1N1 H275Y Proph Competent Out 36y NA None
De Jong
54 2005 H5N1 H274Y Treat Competent In 13y 5 Patient died. Suffered from hypoxia and
pneumonia
Dulek
60 2009 H1N1 H275Y Treat Compromised In 18 m 22 52 days of viral shedding, progressive
pulmonary disease
Gaur
61 2009 H1N1 H275Y Treat Compromised In 10y 14 None reported
Glikman
62 2009 H1N1 H275Y Treat Compromised In 11y 13 Prolonged fever (> 21 days)
Hill-Cawthorne
63 2009 H1N1 H275Y Treat Compromised Out 56y 20 Prolonged fever and cough (2 months)
Ison(1)
64 2001 NA Asp198Asn
Aer285Ala
Proph Compromised In 2y 42 Continued rhinorrhea and dry cough,
progressive respitatory distress,
gastrointestinal bleeding. Eventually died.
Ison(2)
64 2002 H3N2 Arg142Gly
Tyr195Phe
Treat Compromised In 63y 90 Prolonged cough and nasal congestion
Ison(3)
64 2003 H3N2 Glu119Val
Ser31Asn
Treat Compromised In 60y NA Progressive respiratory compromise and
pneumonia, continued respiratory failure.
Died of haemorrhagic stroke.
Le
53 2005 N5N1 H274Y Both Competent Out 14y 4 None. Recovered after 2 weeks.
Memoli
65 2009 H1N1 Amino-
acid
position
245-248
Treat Compromised In 43y 5 None. Recovered after 2 weeks.
Nguyen**
66 2009 H1N1 H27Y Treat Compromised In 14y 17 Died of complications after 2 months
I223R
Rousset**
67 2009 H1N1 H275Y Treat Compromised In 24y 6 Patient died at day 140
Speers
68 2009 H1N1 H275Y Treat Compromised In 38y 3 None. Eventually died
Thabet
69 2009 H1N1 H274Y Treat Compromised In 3y 10 None reported.
Van der Vries*
70 2009 H1N1 H275Y Treat Compromised In 5y 7 Resolutions of symptoms after 3 months
Zanamivir resistance
Gubareva
16 1998 NA 152Argr-
Lys
Treat Compromised In 18 m 8 Not resolved, patients died.
Van der Vries*
70 2009 H1N1 I223R Treat Compromised In 5y 56 Resolutions of symptoms after 3 months
* patient was treated with oseltamivir first, zanamivir second, and developed resistance to both antivirals
** patient also had reduced sensitivity to zanamivir
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Page 10 of 13Additional material
Additional file 1: Additional figure 1 (Figure A.1). Forest plots of
antiviral resistance incidence among oseltamivir studies subgrouped by
study design. The numerator is the number of patients who developed
resistance, and the denominator is the number of patients that received
an NAI.
Additional file 2: Additional figure 2 (Figure A.2). Forest plots of
antiviral resistance incidence among oseltamivir studies subgrouped by
immunocompetent and immunocompromised patients. The numerator is
the number of patients who developed resistance, and the denominator
is the number of patients that received an NAI.
Additional file 3: Additional figure 3 (Figure A.3). Forest plots of
antiviral resistance incidence among oseltamivir studies subgrouped by
out-patients and in-patients. The numerator is the number of patients
who developed resistance, and the denominator is the number of
patients that received an NAI.
Additional file 4: Additional figure 4 (Figure A.4). Forest plots of
antiviral resistance incidence among oseltamivir studies subgrouped by
study age group (adults or children). The numerator is the number of
patients who developed resistance, and the denominator is the number
of patients that received an NAI.
Additional file 5: Additional figure 5 (Figure A.5). Forest plots of
antiviral resistance incidence among oseltamivir studies subgrouped by
intervention purpose. The numerator is the number of patients who
developed resistance, and the denominator is the number of patients
that received an NAI.
Additional file 6: Additional figure 6 (Figure A.6). Forest plots of risk
ratios for associations between antiviral resistance and clinical symptoms.
All risk ratio estimates are crude estimates
Additional file 7: Additional figure 6 (Figure A.6). Forest plots of risk
ratios for associations between antiviral resistance and clinical symptoms.
All risk ratio estimates are crude estimates
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